PRESS-RELEASE filed Aug 11, 2026 at 07:30 ET
Bicara Therapeutics reported Q2 2026 results with a net loss of $0.82 per share, slightly better than the $0.83 consensus estimate. The filing is dominated by a major leadership transition, with CEO Claire Mazumdar stepping down effective January 2027 and President/COO Ryan Cohlhepp taking over, alongside several other C-suite changes. The company's pivotal FORTIFI-HN01 trial remains on track for an interim analysis in mid-2027, and cash runway extends into H1 2029, but the leadership overhaul introduces execution risk at a critical juncture.